PATENT CLAIM ANALYSIS

Application Number: 16065470
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-03
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.

Claim (Index 4):
The method of any of  claims 1 - 3 , wherein cells taken from the patient exhibit expression of a mutant form of CXCR4.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14705809', '13651385', '14947173', '12374311', '15021323']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7187534963706551
- 35 USC 102 Novelty (BERT): 0.4973574610917785
- Combined Prediction Score: 0.6966138928427674
- Mean Citation Score: 171.55361599999995
- Max Citation Score: 182.39935
- Similarity Product: 127.728574862203

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test